Q2 2024 sales rose 22% to 384 MSEK, with EBIT up 42% and strong growth in APAC and Americas. Gross margin improved to 74%, and BioGaia expanded direct distribution in Australia, New Zealand, and Italy.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.